Medical/Pharmaceuticals
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors
Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In Global, For Global" collaboration strategy. NEWARK, Del. and NANJING, China, Feb. 3, 2026 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a globa...
2026-02-03 17:31
7466
ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered inSan Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a key strategic partner, joined hands with multiple enterpr...
2026-02-02 23:00
7321
SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech
- SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling up to $1.5 billion, plus tiered royalties - Genentech wil...
2026-02-02 20:00
4505
Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery"
SHANGHAI, Jan. 31, 2026 /PRNewswire/ -- Amid the surging wave of innovation in China's biopharmaceutical industry, a decade is long enough to witness the full evolution of a sector—from its initial emergence and growth to fundamental transformation. In 2015, as regulatory reform ignited local in...
2026-01-31 16:15
10566
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, to...
2026-01-30 21:00
9752
NEXTBIOMEDICAL Secures Health Canada Approval for Nexsphere-F™ in Musculoskeletal Pain Embolization
SEOUL, South Korea, Jan. 29, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based inSouth Korea, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval fro...
2026-01-29 22:00
7733
MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease
FOSTER CITY, Calif., Jan. 29, 2026 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant bacterial infections, recently announced that the U.S. Food and Drug Administration (FDA) ...
2026-01-29 21:02
6294
XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision
* Global thought leaders presented cutting-edge research at the 2026 International Symposium on Molecular Glue Drug Discovery. * XtalPi unveils the AI-driven XGlue™ platform to enable rapid, closed-loop molecular glue drug discovery. * Cross-sector discussions emphasized the need for bridgin...
2026-01-29 21:00
6118
Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
HONG KONG, Jan. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the ...
2026-01-29 12:51
5338
WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific ...
2026-01-29 10:39
8715
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- QureBio Ltd., a clinical-stage biotech company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today revealed in 2026 ASCO abstract submission a...
2026-01-29 10:21
4792
Nona Biosciences Co-founds Innovative Alliance for Translational Medicine in Immunological Diseases, Advancing a New IIT-Driven Ecosystem
CAMBRIDGE, Mass., Jan. 28, 2026 /PRNewswire/ -- Recently, as a core co-founder and co-organizer, Nona Biosciences participated in the launch of the "Innovative Alliance for Translational Medicine in Immunological Diseases" (the "Alliance") and attended its inauguration ceremony. The Alliance brin...
2026-01-29 09:00
4223
Global Appeal 2026: Education as the Key to Ending Leprosy Stigma and Discrimination
— Launch Event in Brussels Will Be Live-Streamed Worldwide — TOKYO, Jan. 28, 2026 /PRNewswire/ -- The transformative power of education in replacing fear with knowledge and prejudice with empathy lies at the heart of the Global Appeal 2026 to End Stigma and Discrimination against Persons Affect...
2026-01-28 21:00
4050
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
* Ranked in the top one percent among more than 150,000 companies assessed globally * Recognized for strengthened sustainability management across all four assessment categories INCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract developm...
2026-01-28 20:00
7328
First Mold's U.S. Mold Exports Rise 30% in 2025, Driven by Electronics, Automotive, and Medical Manufacturing Demand
ZHONGSHAN, China, Jan. 28, 2026 /PRNewswire/ -- First Mold has announced an increase in its market share. In their recent report, the company announced that in 2025, it shipped over 650 mold units to the US, recording a 30% increase in exports. This announcement shows that First Mold has expanded...
2026-01-28 18:30
4537
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obes...
2026-01-28 12:08
4879
Singapore Eye Research Institute tops ScholarGPS rankings in Ophthalmology
* The Institute has placed #1 in ophthalmology among all non-academic institutes, and #2 in the same field among all institutes, globally. SINGAPORE, Jan. 27, 2026 /PRNewswire/ -- The Singapore Eye Research Institute (SERI) has achieved a landmark milestone inDecember 2025 by securing first pla...
2026-01-28 10:00
3366
Asthma and Allergy Drug Development Is Failing Too Often--A Translational Reset Is Needed: HKEY-AIRx™1.0
BOSTON and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, today announced a translational preclinical strategy,HKEY-AIRxTM1.0 designed to address one of the most persistent problems facing biotech leadership: w...
2026-01-27 22:00
6169
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center...
2026-01-27 22:00
8396
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC)....
2026-01-27 21:00
8818
Week's Top Stories
Most Reposted
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
[Picked up by 321 media titles]
2026-04-09 13:00
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
[Picked up by 312 media titles]
2026-04-09 09:00Visa cements global K-pop connection as Worldwide Tour Sponsor for "BTS WORLD TOUR 'ARIRANG'"
[Picked up by 308 media titles]
2026-04-06 10:00
Tata Power Collaborates with Databricks to Build Future-Ready Data and AI Platform to Accelerate Energy Transition
[Picked up by 302 media titles]
2026-04-10 11:13
UTP Advances Across Key Disciplines in QS World University Rankings By Subject 2026 - Petroleum Engineering Among World's Top 10
[Picked up by 300 media titles]
2026-04-06 16:46
Most Read
NYSE Content Update: Starfish Space Adds Over $100 Million in Funding to Boost Growth
2026-04-07 21:06
6296
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
2026-04-09 13:00
5796
NYSE Content Update: HumanX to Ring Remote Bell with 350+ Speakers On Site
2026-04-08 21:12
5409
